Therapeutic immunomodulation in systemic vasculitis: taking stock.
Identifieur interne : 000487 ( France/Analysis ); précédent : 000486; suivant : 000488Therapeutic immunomodulation in systemic vasculitis: taking stock.
Auteurs : Xavier Puéchal [France] ; Loïc GuillevinSource :
- Joint bone spine [ 1778-7254 ] ; 2013.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux d'origine murine (usage thérapeutique), Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Humains, Immunoglobulines (usage thérapeutique), Immunomodulation, Plasmaphérèse, Prise en charge de la maladie, Rituximab, Résultat thérapeutique, Vascularite systémique (), Vascularite systémique (immunologie).
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- immunologie : Vascularite systémique.
- usage thérapeutique : Anticorps monoclonaux d'origine murine, Immunoglobulines.
- Humains, Immunomodulation, Plasmaphérèse, Prise en charge de la maladie, Rituximab, Résultat thérapeutique, Vascularite systémique.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Murine-Derived (therapeutic use), Disease Management, Humans, Immunoglobulins (therapeutic use), Immunomodulation, Plasmapheresis, Rituximab, Systemic Vasculitis (immunology), Systemic Vasculitis (therapy), Treatment Outcome, Tumor Necrosis Factor-alpha (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal, Murine-Derived, Immunoglobulins.
- immunology : Systemic Vasculitis.
- therapy : Systemic Vasculitis.
- Disease Management, Humans, Immunomodulation, Plasmapheresis, Rituximab, Treatment Outcome.
Abstract
Current data on therapeutic immunomodulation used to treat systemic vasculitides are reviewed in this paper, which also discusses ongoing and future developments in the field. In vasculitides associated with anti-neutrophil cytoplasmic antibodies, rituximab is a validated induction treatment that can serve as an alternative to cyclophosphamide and must be followed by maintenance treatment. In addition, the usefulness of rituximab as maintenance treatment was established recently. Immunoglobulins can be helpful adjuncts, most notably in patients with severe immunodepression. Plasmapheresis is indicated in patients with severe renal failure and may have a role in the treatment of alveolar hemorrhage syndromes. Mepolizumab has produced encouraging preliminary results in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rituximab can be used in cryoglobulinemic vasculitis associated with hepatitis C virus infection when antiviral therapy fails or the disease is severe. Very low doses of interleukin-2 may be helpful in refractory forms. Rituximab is also an option in essential mixed cryoglobulinemia with uncontrolled vasculitis despite glucocorticoid and/or immunosuppressive treatment. In polyarteritis nodosa associated with the hepatitis B virus, a combination of short-course glucocorticoids, plasmapheresis, and antiviral therapy produces excellent outcomes. Intravenous immunoglobulins are used to treat Kawasaki disease, in which they diminish the incidence of coronary artery aneurysms. Several prospective controlled trials are currently assessing tocilizumab in giant-cell arteritis. Rituximab has useful effects in systemic vasculitis associated with rheumatoid arthritis. In Goodpasture's syndrome, plasmapheresis is indicated to clear the antibodies to glomerular membrane antigen, which can induce glomerulonephritis.
DOI: 10.1016/j.jbspin.2012.10.023
PubMed: 23237994
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001761
- to stream PubMed, to step Curation: 001761
- to stream PubMed, to step Checkpoint: 001489
- to stream Ncbi, to step Merge: 000705
- to stream Ncbi, to step Curation: 000705
- to stream Ncbi, to step Checkpoint: 000705
- to stream Main, to step Merge: 002690
- to stream Main, to step Curation: 002682
- to stream Main, to step Exploration: 002682
- to stream France, to step Extraction: 000487
Links to Exploration step
pubmed:23237994Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic immunomodulation in systemic vasculitis: taking stock.</title>
<author><name sortKey="Puechal, Xavier" sort="Puechal, Xavier" uniqKey="Puechal X" first="Xavier" last="Puéchal">Xavier Puéchal</name>
<affiliation wicri:level="4"><nlm:affiliation>Centre de Référence des Maladies Systémiques Auto-Immunes Rares, Vascularites et Sclérodermies Systémiques, Hôpital Cochin, AP-HP, Université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. xavier.puechal@cch.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Référence des Maladies Systémiques Auto-Immunes Rares, Vascularites et Sclérodermies Systémiques, Hôpital Cochin, AP-HP, Université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
<author><name sortKey="Guillevin, Loic" sort="Guillevin, Loic" uniqKey="Guillevin L" first="Loïc" last="Guillevin">Loïc Guillevin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23237994</idno>
<idno type="pmid">23237994</idno>
<idno type="doi">10.1016/j.jbspin.2012.10.023</idno>
<idno type="wicri:Area/PubMed/Corpus">001761</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001761</idno>
<idno type="wicri:Area/PubMed/Curation">001761</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001761</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001489</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001489</idno>
<idno type="wicri:Area/Ncbi/Merge">000705</idno>
<idno type="wicri:Area/Ncbi/Curation">000705</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000705</idno>
<idno type="wicri:Area/Main/Merge">002690</idno>
<idno type="wicri:Area/Main/Curation">002682</idno>
<idno type="wicri:Area/Main/Exploration">002682</idno>
<idno type="wicri:Area/France/Extraction">000487</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic immunomodulation in systemic vasculitis: taking stock.</title>
<author><name sortKey="Puechal, Xavier" sort="Puechal, Xavier" uniqKey="Puechal X" first="Xavier" last="Puéchal">Xavier Puéchal</name>
<affiliation wicri:level="4"><nlm:affiliation>Centre de Référence des Maladies Systémiques Auto-Immunes Rares, Vascularites et Sclérodermies Systémiques, Hôpital Cochin, AP-HP, Université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. xavier.puechal@cch.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Référence des Maladies Systémiques Auto-Immunes Rares, Vascularites et Sclérodermies Systémiques, Hôpital Cochin, AP-HP, Université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
<author><name sortKey="Guillevin, Loic" sort="Guillevin, Loic" uniqKey="Guillevin L" first="Loïc" last="Guillevin">Loïc Guillevin</name>
</author>
</analytic>
<series><title level="j">Joint bone spine</title>
<idno type="eISSN">1778-7254</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived (therapeutic use)</term>
<term>Disease Management</term>
<term>Humans</term>
<term>Immunoglobulins (therapeutic use)</term>
<term>Immunomodulation</term>
<term>Plasmapheresis</term>
<term>Rituximab</term>
<term>Systemic Vasculitis (immunology)</term>
<term>Systemic Vasculitis (therapy)</term>
<term>Treatment Outcome</term>
<term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux d'origine murine (usage thérapeutique)</term>
<term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term>
<term>Humains</term>
<term>Immunoglobulines (usage thérapeutique)</term>
<term>Immunomodulation</term>
<term>Plasmaphérèse</term>
<term>Prise en charge de la maladie</term>
<term>Rituximab</term>
<term>Résultat thérapeutique</term>
<term>Vascularite systémique ()</term>
<term>Vascularite systémique (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived</term>
<term>Immunoglobulins</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vascularite systémique</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Systemic Vasculitis</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Systemic Vasculitis</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux d'origine murine</term>
<term>Immunoglobulines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Management</term>
<term>Humans</term>
<term>Immunomodulation</term>
<term>Plasmapheresis</term>
<term>Rituximab</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Immunomodulation</term>
<term>Plasmaphérèse</term>
<term>Prise en charge de la maladie</term>
<term>Rituximab</term>
<term>Résultat thérapeutique</term>
<term>Vascularite systémique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Current data on therapeutic immunomodulation used to treat systemic vasculitides are reviewed in this paper, which also discusses ongoing and future developments in the field. In vasculitides associated with anti-neutrophil cytoplasmic antibodies, rituximab is a validated induction treatment that can serve as an alternative to cyclophosphamide and must be followed by maintenance treatment. In addition, the usefulness of rituximab as maintenance treatment was established recently. Immunoglobulins can be helpful adjuncts, most notably in patients with severe immunodepression. Plasmapheresis is indicated in patients with severe renal failure and may have a role in the treatment of alveolar hemorrhage syndromes. Mepolizumab has produced encouraging preliminary results in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rituximab can be used in cryoglobulinemic vasculitis associated with hepatitis C virus infection when antiviral therapy fails or the disease is severe. Very low doses of interleukin-2 may be helpful in refractory forms. Rituximab is also an option in essential mixed cryoglobulinemia with uncontrolled vasculitis despite glucocorticoid and/or immunosuppressive treatment. In polyarteritis nodosa associated with the hepatitis B virus, a combination of short-course glucocorticoids, plasmapheresis, and antiviral therapy produces excellent outcomes. Intravenous immunoglobulins are used to treat Kawasaki disease, in which they diminish the incidence of coronary artery aneurysms. Several prospective controlled trials are currently assessing tocilizumab in giant-cell arteritis. Rituximab has useful effects in systemic vasculitis associated with rheumatoid arthritis. In Goodpasture's syndrome, plasmapheresis is indicated to clear the antibodies to glomerular membrane antigen, which can induce glomerulonephritis. </div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
<orgName><li>Université Paris-Descartes</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Guillevin, Loic" sort="Guillevin, Loic" uniqKey="Guillevin L" first="Loïc" last="Guillevin">Loïc Guillevin</name>
</noCountry>
<country name="France"><region name="Île-de-France"><name sortKey="Puechal, Xavier" sort="Puechal, Xavier" uniqKey="Puechal X" first="Xavier" last="Puéchal">Xavier Puéchal</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000487 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000487 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= TocilizumabV1 |flux= France |étape= Analysis |type= RBID |clé= pubmed:23237994 |texte= Therapeutic immunomodulation in systemic vasculitis: taking stock. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:23237994" \ | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \ | NlmPubMed2Wicri -a TocilizumabV1
This area was generated with Dilib version V0.6.34. |